TITLE

Macugen account goes to Medicus

AUTHOR(S)
Arnold, Matthew
PUB. DATE
May 2004
SOURCE
Medical Marketing & Media;May2004, Vol. 39 Issue 5, p10
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Pfizer and Eyetech Pharmaceuticals have appointed Medicus New York to handle professional advertising for their co-marketed Macugen drug for macular degeneration. Account is Medicus Group's first formal assignment from Pfizer; Parent firm Publicis Groupe's work with Pfizer in the past; Macugen is in Phase III clinical trials; Expected launch in first quarter 2005; Rival drug Visudyne from Novartis.
ACCESSION #
13048752

 

Related Articles

  • AMD: A Revolution In Therapy Begins. Rosenfeld, Philip // Review of Ophthalmology;Mar2005, Vol. 12 Issue 3, p96 

    Assesses the effectiveness of Macugen, an ophthalmic drug from Eyetech Pharmaceuticals Inc. and Pfizer Inc., that specifically targets the vascular endothelial growth factor (VEGF) to treat age-related macular degeneration. Correlation between elevated levels of VEGF and various diseases that...

  • New Eye Drug Approved. Mirasol, Feliza // Chemical Market Reporter;1/10/2005, Vol. 267 Issue 2, p10 

    Reports on the approval of the U.S. Food and Drug Administration to new eye drug Macugen of Eyetech Pharmaceuticals Inc. and co-developer Pfizer Inc. Use of Macugen in the treatment of neovascular age-related macular degeneration; Price of the drug; Development of Macugen.

  • FDA Approves Eyetech/Pfizers Macugen.  // Review of Ophthalmology;Jan2005, Vol. 12 Issue 1, p4 

    The article reports that the U.S. food and Drug Administration has approved Macugen injection for the treatment of neovascular age-related macular degeneration. The injection has been developed by Eyetech Pharmaceuticals Inc. and Pfizer Inc. Macugen is the first in a new class of ophthalmic...

  • Priority review for Pfizer, Eyetech AMD drug.  // PharmaWatch: Biotechnology;October 2004, Vol. 3 Issue 10, p11 

    The article reports that Macugen, a treatment for age-related macular degeneration jointly developed by Pfizer Corp. and Eyetech Pharmaceuticals Inc. has been granted a priority review designation by the U.S.Food and Drug Administration (FDA). The companies submitted the final portion of the new...

  • Changes in pegaptanib labeling prompted by adverse reactions. Charters, Lynda // Ophthalmology Times;5/15/2006, Vol. 31 Issue 10, p8 

    The article focuses on the changes in the product labeling for pegaptanib sodium injection made by OSI Pharmaceuticals Inc., Eyetech Pharmaceuticals Inc. and Pfizer Inc. The injection was approved by the United States Food and Drug Administration for the treatment of neovascular age-related...

  • Pegaptanib sodium injection available for treatment of AMD-related CNV. Guttman, Cheryl // Ophthalmology Times;1/15/2005, Vol. 30 Issue 2, p1 

    This article reports that the FDA approved pegaptanib sodium injection by Macugen, Eyetech Pharmaceuticals and Pfizer Ophthalmics for the treatment of neovascular age-related macular degeneration (AMD) on December 17. With the regulatory agency's decision, pegaptanib sodium became the first...

  • Pipeline.  // Medical Marketing & Media;Feb2005, Vol. 40 Issue 2, p12 

    The article presents news from the pharmaceutical industry. Pfizer Inc. received a setback when the FDA classified its newly approved nerve pain drug Lyrica as a controlled substance, resulting in additional requirements for doctors and pharmacists. Pfizer had been counting on Lyrica to offset...

  • Pfizer Funds Anti-Blindness Treatment. Branch Jr., Al // Pharmaceutical Executive;Feb2003, Vol. 23 Issue 2, p28 

    Reports on the partnership between Pfizer Inc. and Eyetech Pharmaceutical for a drug development in the U.S. Medication to treat age-related macular degeneration; Insurance coverage for the medicine; Investment of Pfizer Inc. for the drug development.

  • Injection approved for macular degeneration.  // Drug Topics;1/10/2005, Vol. 149 Issue 1, p8 

    Reports on the approval of Pegaptanib sodium injection 0.3 mg from Eyetech Pharmaceuticals/Pfizer, for the treatment of neovascular age-related macular degeneration.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics